Abstract
Hepatitis B remains a global health issue, despite an effective vaccine. Mother to child transmission (MTCT) of hepatitis B has become increasingly recognized, especially in those patients with high maternal viremia. In a woman of childbearing age, carefully assessing disease status and urgency of treatment is key, along with discussion of family planning, timing and choice of therapy. In a pregnant patient with chronic hepatitis B, treatment in the third trimester may be considered in those with HBV DNA levels >107 copies (2 × 106 IU/ml) and may reduce the perinatal transmission rate, but a thorough discussion of the risks and benefits is essential. Duration of antiviral therapy depends upon the indication for treatment as those individuals treated for active disease from the hepatitis B would need long term therapy, while those treated in the third trimester only to prevent MTCT may have therapy discontinued.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
